Stock Ratios
Making an investment decision in the stock market involves a certain amount of risk, so it's important to thoroughly review a company's stock before making any decisions. Stock float, number of short positions and outstanding shares are among the many factors an investor should take into account.
profit margin TTM
-38.98%
operating margin TTM
-21.6%
revenue TTM
190.69 Million
revenue per share TTM
1.48$
valuation ratios | |
|---|---|
| pe ratio | -8.34 |
| peg ratio | 0.06 |
| price to book ratio | 2.09 |
| price to sales ratio | 3.25 |
| enterprise value multiple | -26.45 |
| price fair value | 2.09 |
profitability ratios | |
|---|---|
| gross profit margin | 53.23% |
| operating profit margin | -21.6% |
| pretax profit margin | -19.75% |
| net profit margin | -38.98% |
| return on assets | -18.03% |
| return on equity | -23.53% |
| return on capital employed | -12.31% |
liquidity ratios | |
|---|---|
| current ratio | 4.48 |
| quick ratio | 3.86 |
| cash ratio | 0.88 |
efficiency ratios | |
|---|---|
| days of inventory outstanding | 197.27 |
| operating cycle | 287.85 |
| days of payables outstanding | 31.74 |
| cash conversion cycle | 256.10 |
| receivables turnover | 4.03 |
| payables turnover | 11.50 |
| inventory turnover | 1.85 |
debt and solvency ratios | |
|---|---|
| debt ratio | 0.06 |
| debt equity ratio | 0.08 |
| long term debt to capitalization | 0.00 |
| total debt to capitalization | 0.08 |
| interest coverage | -25.34 |
| cash flow to debt ratio | -0.23 |
cash flow ratios | |
|---|---|
| free cash flow per share | -0.09 |
| cash per share | 2.02 |
| operating cash flow per share | -0.05 |
| free cash flow operating cash flow ratio | 2.00 |
| cash flow coverage ratios | -0.23 |
| short term coverage ratios | -0.64 |
| capital expenditure coverage ratio | -1.00 |
Frequently Asked Questions
When was the last time Cytek Biosciences, Inc. (NASDAQ:CTKB) reported earnings?
Cytek Biosciences, Inc. (CTKB) published its most recent earnings results on 05-08-2026.
What is Cytek Biosciences, Inc.'s current ROE?
An investor's main concern is the profitability ratios of a company so that they are able to understand how it performs financially. Investors are interested in finding out how effectively a business is using their cash to produce earnings, which is why return on equity (ROE) ratio is important. Cytek Biosciences, Inc. (NASDAQ:CTKB)'s trailing twelve months ROE is -23.53%.
What are ROA telling us?
The Return on Assets (ROA) ratio measures how profitable a company is relative to its total assets. Cytek Biosciences, Inc. (CTKB) currently has a ROA of -18.03%. Companies that manage their assets effectively will have greater returns, while those that do so poorly would suffer lower returns.
Where did CTKB's net profit margin stand at?
CTKB reported a profit margin of -38.98% in the last quarter. A company's profit margin, also known as its revenue ratio or gross profit ratio, reflects the amount of revenue that an organization earns compared to its net income. In general, a higher ratio implies greater profit, and vice versa.
What is CTKB's short-term liquidity position?
Apple's current ratio, which measures its ability to pay short-term obligations, was 4.48 in the most recent quarter. The quick ratio stood at 3.86, with a Debt/Eq ratio of 0.08.